NCT03304678 2026-02-18
Discovery of Sirolimus Sensitive Biomarkers in Blood
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
12 trialsNCT05467397 2026-01-21
Feasibility of [11C]Acetate-PET in LAM and TSC
Brigham and Women's Hospital
Phase 1/2 Active not recruiting
NCT01353209 2024-04-17
TRAIL
University of Cincinnati
Phase 2 Completed
NCT00414648 2023-11-02
MILES
University of Cincinnati
Phase 3 Completed
NCT03253913 2023-02-01
RESULT
University of Cincinnati
Phase 2 Completed
NCT02484664 2022-01-20
COLA
Brigham and Women's Hospital
Phase 2 Completed
NCT03525834 2021-09-09
Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
Novartis
Phase 4 Completed
NCT01059318 2020-11-19
A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Novartis
Phase 2 Completed
NCT02061397 2020-08-25
SOS
University of Pennsylvania
Phase 1/2 Completed
NCT03131999 2020-06-16
LAMP-1
Medical University of South Carolina
Phase 1/2 Completed
NCT01687179 2018-10-11
SAIL
Brigham and Women's Hospital
Phase 1 Completed
NCT00005906 2010-04-30
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed